BioCentury
ARTICLE | Emerging Company Profile

Metabolic regulation

ImmunoMet aims to block metabolism in cancer and immunosuppressive cells

June 16, 2017 6:14 PM UTC

ImmunoMet Therapeutics Inc. is developing a portfolio of biguanide derivatives that have the anticancer properties of metformin but are better optimized for the indication. Some starve drug-resistant cancers by blocking a metabolic pathway they rely on, while others inhibit metabolism in immunosuppressive cells.

One way cancer cells become resistant to chemotherapy is by switching their primary method of metabolism from glycolysis to oxidative phosphorylation. COO Benjamin Cowen said evidence is mounting that the biguanide metformin can inhibit this method of metabolism...